2022

• Impact of systematic medication review in emergency department on patients' post-discharge outcomes-A randomized controlled clinical trial. Nymoen LD, Flatebø TE, Moger TA, Øie E, Molden E, Viktil KK. PLoS One. 2022 Sep 19;17(9):e0274907.
• Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis. Hart XM, Hiemke C, Eichentopf L, Lense XM, Clement HW, Conca A, Faltraco F, Florio V, Grüner J, Havemann-Reinecke U, Molden E, Paulzen M, Schoretsanitis G, Riemer TG, Gründer G. Psychopharmacology (Berl). 2022 Nov;239(11):3377-3391.
• Pharmacogenomics in treatment of depression and psychosis: an update.
  Jukic M, Milosavljević F, Molden E, Ingelman-Sundberg M. Trends Pharmacol Sci. 2022 Dec;43(12):1055-1069.
• Falsely low phosphatidylethanol may be associated with biomarkers of haemolytic disease. Årving A, Hilberg T, Sovershaev M, Bogstrand ST, Høiseth G. Basic Clin Pharmacol Toxicol. 2022 Nov 12. doi: 10.1111/bcpt.13814
• Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy. Halvorsen LV, Bergland OU, Søraas CL, Larstorp ACK, Hjørnholm U, Kjær VN, Kringen MK, Clasen PE, Haldsrud R, Kjeldsen SE, Rostrup M, Fadl Elmula FEM, Opdal MS, Høieggen A. J Am Heart Assoc. 2022 Sep 20;11(18):e025879.
• Mechanical-Stress-Related Epigenetic Regulation of ZIC1 Transcription Factor in the Etiology of Postmenopausal Osteoporosis. Datta HK, Kringen MK, Tuck SP, Salpingidou G, Olstad OK, Gautvik KM, Cockell SJ, Gautvik VT, Prediger M, Wu JJ, Birch MA, Reppe S. Int J Mol Sci. 2022 Mar 9;23(6):2957.
• Impact of NFIB and CYP1A variants on clozapine serum concentration-A retrospective naturalistic cohort study on 526 patients with known smoking habits. Lenk HÇ, Løvsletten Smith R, O'Connell KS, Jukić MM, Kringen MK, Andreassen OA, Ingelman-Sundberg M, Molden E. Clin Transl Sci. 2022 Sep 24. doi: 10.1111/cts.13422.
• Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia. Selli AL, Kuzmiszyn AK, Smaglyukova N, Kondratiev T, Fuskevåg OM, Sager G, Dietrichs ES. Scand J Trauma Resusc Emerg Med. 2022 Dec 15;30(1):73.
• Genotyping av pasienter behandlet med selektive serotoninreopptakshemmere.
  Solhaug V, Haslemo T, Kringen MK, Molden E, Dietrichs ES. Tidsskr Nor Laegeforen. 2022 Sep 26;142(13).
• Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers. Faraj P, Hermansen A, Molden E, Hole K. Ther Drug Monit. 2022 Dec 1;44(6):720-728.
• Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population. Bråten LS, Ingelman-Sundberg M, Jukic MM, Molden E, Kringen MK. Clin Transl Sci. 2022 Jun 6. doi: 10.1111/cts.13347
• Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway. Gedde-Dahl A, Spigset O, Molden E. Eur J Clin Pharmacol. 2022 Jul 25. doi: 10.1007/s00228-022-03364-5.
• Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients. Frederiksen T, Smith RL, Jukic MM, Molden E. J Clin Psychopharmacol. 2022 Jul-Aug 01;42(4):396-399.
• Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment: A Retrospective Pilot Study. Kyllesø L, Smith RL, Wollmann BM, Karlstad Ø, Andreassen OA, Molden E. J Clin Psychopharmacol. 2022 Aug 2. doi: 10.1097/JCP.0000000000001585.
• Treatment of Cardiovascular Dysfunction with PDE3-Inhibitors in Moderate and Severe Hypothermia-Effects on Cellular Elimination of Cyclic Adenosine Monophosphate and Cyclic Guanosine Monophosphate. Kuzmiszyn AK, Selli AL, Smaglyukova N, Kondratiev T, Fuskevåg OM, Lyså RA, Ravna AW, Tveita T, Sager G, Dietrichs ES. Front Physiol. 2022 Jul 13;13:923091.
• Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. Eide Kvitne K, Hole K, Krogstad V, Wollmann BM, Wegler C, Johnson LK, Hertel JK, Artursson P, Karlsson C, Andersson S, Andersson TB, Sandbu R, Hjelmesæth J, Skovlund E, Christensen H, Jansson-Löfmark R, Åsberg A, Molden E, Robertsen I. Eur J Clin Pharmacol. 2022 Aug;78(8):1289-1299.
• Frequency of postmortem ethanol formation in blood, urine and vitreous humor - Improving diagnostic accuracy with the use of ethylsulphate and putrefactive alcohols. Oshaug K, Kronstrand R, Kugelberg FC, Kristoffersen L, Mørland J, Høiseth G. Forensic Sci Int. 2022 Feb;331:111152. doi: 10.1016/j.forsciint.2021.111152.
• Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed controlled trial.
  Kvitne KE, Robertsen I, Skovlund E, Christensen H, Krogstad V, Wegler C, Angeles PC, Wollmann BM, Hole K, Johnson LK, Sandbu R, Artursson P, Karlsson C, Andersson S, Andersson TB, Hjelmesaeth J, Jansson-Löfmark R, Åsberg A.
  Clin Transl Sci. 2022 Jan;15(1):221-233.
• Prediction of Ventricular Arrhythmias by QRS/QTc - Ratio in Citalopram or Escitalopram Intoxication. Dietrichs ES, Smith GL.
  Front Med (Lausanne). 2022 Mar 16;9:866454. doi: 10.3389/fmed.2022.866454
• Time to replace the term neuroleptic malignant syndrome with antidopaminergic syndrome? Dietrichs ES, Dietrichs E. Lancet Psychiatry. 2022 May;9(5):348.
• An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.
  de Leon J et al (inkl. Smith RL, Molden E). Pharmacopsychiatry. 2022 Mar;55(2):73-86.
• The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients.
  Lenk HÇ, Klöditz K, Johansson I, Smith RL, Jukić MM, Molden E, Ingelman-Sundberg M. Clin Pharmacol Ther. 2022 May;111(5):1165-1174.
• Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia. Smith RL, Wollmann BM, Kyllesø L, Tran TTA, Tveito M, Molden E.
  J Clin Psychopharmacol. 2022 Jan-Feb 01;42(1):43-50.
• Effects of a novel UGT2B haplotype and UGT1A4*3 allele variants on glucuronidation of clozapine in vivo. Smith RL, Wollmann BM, Kausberg M, Mæland S, Tveito M, Connell KO, Molden E, Kringen MK. Curr Drug Metab. 2022 Feb 1.  doi: 10.2174/1389200223666220201152953.
• In Vitro Apixaban Removal By CytoSorb Whole Blood Adsorber: An Experimental Study. Røed-Undlien H, Schultz NH, Lunnan A, Husebråten IM, Wollmann BM, Molden E, Bjørnstad JL. J Cardiothorac Vasc Anesth. 2022 Jan 31:S1053-0770(22)00072-6. doi: 10.1053/j.jvca.2022.01.038.
• Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Trubetskoy V et al (inkl. Molden E). Nature. 2022 Apr;604(7906):502-508.
• Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Blokland GAM et al (inkl. Molden E). Biol Psychiatry. 2022 Jan 1;91(1):102-117. doi: 10.1016/j.biopsych.2021.02.972.
• Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study. Veddeng S, Madland H, Molden E, Wyller TB, Romskaug R. BMC Geriatr. 2022 Mar 23;22(1):242.
• Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. Kvitne KE, Krogstad V, Wegler C, Johnson LK, Kringen MK, Hovd MH, Hertel JK, Heijer M, Sandbu R, Skovlund E, Artursson P, Karlsson C, Andersson S, Andersson TB, Hjelmesaeth J, Åsberg A, Jansson-Löfmark R, Christensen H, Robertsen I. Br J Clin Pharmacol. 2022 Apr 11. doi: 10.1111/bcp.15349.
• Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. Chalabianloo F, Høiseth G, Vold JH, Johansson KA, Kringen MK, Dalgard O, Ohldieck C, Druckrey-Fiskaaen KT, Aas C, Løberg EM, Bramness JG, Fadnes LT. J Addict Dis. 2022 Mar 31:1-11.
• Mechanical-Stress-Related Epigenetic Regulation of ZIC1 Transcription Factor in the Etiology of Postmenopausal Osteoporosis. Datta HK, Kringen MK, Tuck SP, Salpingidou G, Olstad OK, Gautvik KM, Cockell SJ, Gautvik VT, Prediger M, Wu JJ, Birch MA, Reppe S. Int J Mol Sci. 2022 Mar 9;23(6):2957.
• The alcohol marker phosphatidylethanol is closely related to AST, GGT, ferritin and HDL-C. Høiseth G, Hilberg T, Trydal T, Husa A, Vindenes V, Bogstrand ST.
  Basic Clin Pharmacol Toxicol. 2022 Jan;130(1):182-190.

2021

• Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. Chalabianloo F, Fadnes LT, Høiseth G, Ohldieck C, Vold JH, Aas C, Løberg EM, Johansson KA, Bramness JG. Subst Abuse Treat Prev Policy. 2021 May 3;16(1):39.
• The alcohol marker phosphatidylethanol is closely related to AST, GGT, ferritin and HDL-C. Høiseth G, Hilberg T, Trydal T, Husa A, Vindenes V, Bogstrand ST.
  Basic Clin Pharmacol Toxicol. 2021 Sep 30. doi: 10.1111/bcpt.13662.
• Is hypothermia more neuroprotective than avoiding fever after cardiac arrest?
  Dietrichs ES, Myles R, Smith G. Cardiovasc Res. 2021 Nov 1;117(12):e159-e161. doi: 10.1093/cvr/cvab297.
• Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Waade RB, Solhaug V, Høiseth G. Br J Clin Pharmacol. 2021 May;87(5):2228-2235.
• Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed controlled trial. Kvitne KE, Robertsen I, Skovlund E, Christensen H, Krogstad V, Wegler C, Angeles PC, Wollmann BM, Hole K, Johnson LK, Sandbu R, Artursson P, Karlsson C, Andersson S, Andersson TB, Hjelmesaeth J, Jansson-Löfmark R, Åsberg A.
  Clin Transl Sci. 2021 Aug 26. doi: 10.1111/cts.13142. Online ahead of print.
• Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. Jukić MM, Smith RL, Molden E, Ingelman-Sundberg M. Clin Pharmacol Ther. 2021 Sep;110(3):750-758.
• Resistance to ventricular fibrillation predicted by the QRS/QTc - Ratio in an intact rat model of hypothermia/rewarming. Dietrichs ES, Selli AL, Kondratiev T, McGlynn K, Smith G, Tveita T. Cryobiology. 2021 Feb;98:33-38.
• Molecular modeling study of the testosterone metabolizing enzyme UDP-glucuronosyltransferase 2B17. Trane I, Sager G, Dietrichs ES, Westrheim Ravna A. Bioorg Med Chem. 2021 Apr 15;36:116060. doi: 10.1016/j.bmc.2021.116060. Epub 2021 Feb 20.
• Inhibition of ABCC5-mediated cGMP transport by progesterone, testosterone and their analogues. Odland SU, Ravna AW, Smaglyukova N, Dietrichs ES, Sager G. J Steroid Biochem Mol Biol. 2021 Oct;213:105951. doi: 10.1016/j.jsbmb.2021.105951. Epub 2021 Jul 13.
• Cardiovascular Effects of Epinephrine During Experimental Hypothermia (32°C) With Spontaneous Circulation in an Intact Porcine Model. Mohyuddin R, Dietrichs ES, Sundaram P, Kondratiev T, Figenschou MF, Sieck GC, Tveita T. Front Physiol. 2021 Sep 6;12:718667. doi: 10.3389/fphys.2021.718667. eCollection 2021.
• Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors - Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP.
  Selli AL, Kuzmiszyn AK, Smaglyukova N, Kondratiev TV, Fuskevåg OM, Lyså RA, Ravna AW, Tveita T, Sager G, Dietrichs ES. Front Physiol. 2021 Jul 30;12:695779. doi: 10.3389/fphys.2021.695779. eCollection 2021.
• CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry. Molden E, Jukić MM. Front Pharmacol. 2021 Apr 22;12:650750. doi: 10.3389/fphar.2021.650750. eCollection 2021.
• Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. Kyllesø L, Smith RL, Karlstad Ø, Andreassen OA, Molden E. CNS Drugs. 2021 Sep;35(9):999-1008.
  
• Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients. Tveito M, Høiseth G, Haslemo T, Molden E, Smith RL. Eur J Clin Pharmacol. 2021 Aug;77(8):1201-1208.
  
• Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low clearance. Riede J, Wollmann BM, Molden E, Ingelman-Sundberg M. Drug Metab Dispos. 2021 Jun 1:DMD-AR-2020-000340. doi: 10.1124/dmd.120.000340. Online ahead of print.
• Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies. Molden E. Expert Opin Drug Metab Toxicol. 2021 Sep 6:1-11.
• Genetic Association Between Schizophrenia and Cortical Brain Surface Area and Thickness. Cheng W, Frei O, van der Meer D, Wang Y, O'Connell KS, Chu Y, Bahrami S, Shadrin AA, Alnæs D, Hindley GFL, Lin A, Karadag N, Fan CC, Westlye LT, Kaufmann T, Molden E, Dale AM, Djurovic S, Smeland OB, Andreassen OA. JAMA Psychiatry. 2021 Sep 1;78(9):1020-1030.
• Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. Frederiksen T, Smith RL, Wollmann BM, Areberg J, Molden E. Clin Pharmacokinet. 2021 Jun 14. doi: 10.1007/s40262-021-01029-7. Online ahead of print.
• Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Blokland GAM et al. (inkl Molden E). Biol Psychiatry. 2021 Mar 23:S0006-3223(21)01139-2. doi: 10.1016/j.biopsych.2021.02.972. Online ahead of print.
• Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.
  Hole K, Arnestad M, Molden E, Haslemo T. J Clin Psychopharmacol. 2021 May-Jun 01;41(3):281-285.
• A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram. Bråten LS, Haslemo T, Jukic MM, Ivanov M, Ingelman-Sundberg M, Molden E, Kringen MK. Clin Pharmacol Ther. 2021 Sep;110(3):786-793.
• Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. JAMA Psychiatry. 2021 Mar 1;78(3):270-280.
• The acute phase response protein SERPINA3 is increased in tear fluid from the unaffected eyes of patients with unilateral acute anterior uveitis. Eidet JR, Akopian M, Olstad OK, Jørstad ØK, Moe MC, Petrovski G, Pepaj M.
  J Ophthalmic Inflamm Infect. 2021 Jul 2;11(1):19. doi: 10.1186/s12348-021-00249-z.
  
  
• Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders.
  Smith RL, Tveito M, Kyllesø L, Jukic MM, Ingelman-Sundberg M, Andreassen OA, Molden E. Schizophr Res. 2021 Feb;228:590-596. 
  
  
• Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. Tveito M, Smith RL, Molden E, Høiseth G.
  Eur J Clin Pharmacol. 2021 Feb;77(2):215-221.
  
  
  
• Alcohol Consumption, HDL-Cholesterol and Incidence of Colon and Rectal Cancer: A Prospective Cohort Study Including 250,010 Participants. Tverdal A, Høiseth G, Magnus P, Næss Ø, Selmer R, Knudsen GP, Mørland J. Alcohol Alcohol. 2021 Feb 19:agab007. doi: 10.1093/alcalc/agab007. Online ahead of print. PMID: 33604595
  
  
• Associations of Binge Drinking With the Risks of Ischemic Heart Disease and Stroke: A Study of Pooled Norwegian Health Surveys. Degerud E, Høiseth G, Mørland J, Ariansen I, Graff-Iversen S, Ystrom E, Zuccolo L, Tell GS, Næss Ø. Am J Epidemiol. 2021 Aug 1;190(8):1592-1603.
  

• Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
  

  Thorén L, Lindh JD, Ackehed G, Kringen MK, Hall P, Bergh J, Molden E, Margolin S, Eliasson E. Br J Clin Pharmacol. 2021 Mar;87(3):1243-1252.

  
  
• Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes. Krogstad V, Peric A, Robertsen I, Kringen MK, Vistnes M, Hjelmesæth J, Sandbu R, Johnson LK, Angeles PC, Jansson-Löfmark R, Karlsson C, Andersson S, Åsberg A, Andersson TB, Christensen H. J Pharm Sci. 2021 Jan;110(1):432-437.

• European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Vázquez M, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, de Leon J.  J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):140-147.

2020

• Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders.
  Smith RL, Tveito M, Kyllesø L, Jukic MM, Ingelman-Sundberg M, Andreassen OA, Molden E. Schizophr Res. 2020 Nov 18:S0920-9964(20)30565-X. doi: 10.1016/j.schres.2020.11.025
• Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Waade RB, Solhaug V, Høiseth G.
  Br J Clin Pharmacol. 2020 Oct 28. doi: 10.1111/bcp.14626
• Bruk av farmakogenetiske tester i psykiatrien. Haslemo T, Solhaug V. NFT. 2020 des 14; 9: 38-41.
• The Relationship Between Ingested Dose of Ethanol and Amount of Ethyl Glucuronide Formed in Blood. Fosen JT, Mørland J, Høiseth G.
  J Anal Toxicol. 2020 Dec 12;44(8):861-863.

• Use of Antidepressants in Older People during a 10-Year Period: An Observational Study on Prescribed Doses and Serum Levels.
  Tveit K, Hermann M, Waade RB, Nilsen RM, Wallerstedt SM, Molden E.
  Drugs Aging. 2020 Sep;37(9):691-701. doi: 10.1007/s40266-020-00784-9
• Nøytropeni ved behandling med antipsykotika. Torp HA, Nystøy B. Tidsskr Nor Laegeforen. 2020 May 25;140(8).
  

  
  
• Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. Kyllesø L, Smith RL, Karlstad Ø, Andreassen OA, Molden E.
  NPJ Schizophr. 2020 Jul 17;6(1):17.
  
• Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: a systematic review. Westergren T, Narum S, Klemp M. BMJ Open. 2020 Jul 20;10(7):e036412. doi: 10.1136/bmjopen-2019-036412.
• Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits.
  
  Smith RL, O'Connell K, Athanasiu L, Djurovic S, Kringen MK, Andreassen OA, Molden E. Transl Psychiatry. 2020 Jun 19;10(1):198. doi: 10.1038/s41398-020-00888-1.

• Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients.

  Smith RL, Tveito M, Kyllesø L, Jukic MM, Ingelman-Sundberg M, Andreassen OA, Molden E. Eur Neuropsychopharmacol. 2020 Aug;37:64-69. doi: 10.1016/j.euroneuro.2020.06.007.

  
  
• Effect of Clinical Geriatric Assessments and Collaborative Medication Reviews by Geriatrician and Family Physician for Improving Health-Related Quality of Life in Home-Dwelling Older Patients Receiving Polypharmacy: A Cluster Randomized Clinical Trial. Romskaug R, Skovlund E, Straand J, Molden E, Kersten H, Pitkala KH, Lundqvist C, Wyller TB. JAMA Intern Med. 2020 Feb 1;180(2):181-189.
  
  
• The Relation Between Ingested Dose of Ethanol and Amount of Ethyl Glucuronide Formed in Blood. Fosen JT, Mørland J, Høiseth G.
  J Anal Toxicol. 2020 Jul 31:bkaa090. doi: 10.1093/jat/bkaa090.
  
  
  
• Evaluating the hip-flask defence using analytical data from ethanol and ethyl glucuronide. A comparison of two models. Höiseth G, Nilsson GH, Lundberg R, Forsman M, Kronstrand C, Nyström I, Oscarsson C, Ericsson E, Cherma MD, Ahlner J, Kugelberg FC, Kronstrand R. Forensic Sci Int. 2020 Aug 26;316:110409. doi: 10.1016/j.forsciint.2020.110409
  
  
• Association of coincident self-reported mental health problems and alcohol intake with all-cause and cardiovascular disease mortality: A Norwegian pooled population analysis. Degerud E, Høiseth G, Mørland J, Ariansen I, Graff-Iversen S, Ystrom E, Zuccolo L, Næss Ø.PLoS Med. 2020 Feb 3;17(2):e1003030
  
• Fatal liver failure after therapeutic doses of paracetamol in a patient with Duchenne muscular dystrophy and atypical pharmacogenetic profile of drug-metabolizing enzymes. Lao YE, Molden E, Kringen MK, Annexstad EJ, Saeverud HA, Jacobsen D, Hovda KE. Basic Clin Pharmacol Toxicol. 2020 Jan 24. doi: 10.1111/bcpt.13389. Online ahead of print.
  
• Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study. Anstensrud AK, Molden E, Haug HJ, Qazi R, Muriq H, Fosshaug LE, Spigset O, Øie E. Eur J Clin Pharmacol. 2020 May;76(5):673-683. 
• Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy. Romskaug R, Wyller TB, Straand J, Kersten H, Molden E. Drugs Aging. 2020 Apr 29. doi: 10.1007/s40266-020-00763-0. Online ahead of print.
• The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort. Kringen MK, Bråten LS, Haslemo T, Molden E.
  J Clin Psychopharmacol. 2020 Mar/Apr;40(2):137-144.
  
• Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. Tveito M, Molden E, Høiseth G, Correll CU, Smith RL.
  Eur J Clin Pharmacol. 2020 Jan;76(1):41-49.
• Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Bråten LS, Haslemo T, Jukic MM, Ingelman-Sundberg M, Molden E, Kringen MK. Neuropsychopharmacology. 2020 Feb;45(3):570-576.
• A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity. Krogstad V, Peric A, Robertsen I, Kringen MK, Wegler C, Angeles PC, Hjelmesæth J, Karlsson C, Andersson S, Artursson P, Åsberg A, Andersson TB, Christensen H. Drug Metab Dispos. 2020 Jan;48(1):8-17.
• Oral Fluid to Blood Concentration Ratios of Different Psychoactive Drugs in Samples from Suspected Drugged Drivers.
  

  Bakke E, Høiseth G, Furuhaugen H, Berg T, Arnestad M, Gjerde H.

  Ther Drug Monit. 2020 Oct;42(5):795-800.
• Blood concentrations of designer benzodiazepines: Relation to impairment and findings in forensic cases. Heide G, Høiseth G, Middelkoop G, Øiestad ÅML. J Anal Toxicol. 2020 Dec 12;44(8):905-914.

2019

• Nye anbefalinger ved serumkonsentrasjonsmålinger av sentralstimulerende legemidler. Frost J, Bernard JP, Dietrichs ES, Kjeldstadli K, Riedel B, Skråstad RB, Vevelstad M, Helland A. Tidsskr Nor Laegeforen. 2019 Sep 23;139(13).
  
• A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia. Solberg DK, Refsum H, Andreassen OA, Bentsen H. Acta Neuropsychiatr. 2019 Aug;31(4):202-212.
  
• Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. Lea M, Mowe M, Mathiesen L, Kvernrød K, Skovlund E, Molden E. PLoS One. 2019 Jul 22;14(7):e0220071.
  
• Forskrivning av antipsykotika til hjemmeboende eldre 2006–18. Tveito M, Handal M, Engedal K, Smith RL, Høiseth G, Skurtveit S. Tidsskr Nor Laegeforen. 2019 Oct 29;139(16).
  
• The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections. Tveito M, Smith RL, Høiseth G, Molden E. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):561-566
  
• Reduction in N-Desmethylclozapine Level Is Determined by Daily Dose But Not Serum Concentration of Valproic Acid-Indications of a Presystemic Interaction Mechanism. Smith RL, Kyllesø L, Haslemo T, Andreassen OA, Molden E. Ther Drug Monit. 2019 Aug;41(4):503-508.
  
• Detection Time of Oxazepam and Zopiclone in Urine and Oral Fluid after Experimental Oral Dosing. Bruun LD, Kjeldstadli K, Temte V, Birdal M, Bachs L, Langødegård M, Strand DH, Gaare KI, Øiestad E, Høiseth G. J Anal Toxicol. 2019 Jun 1;43(5):369-377.
  
• Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. Danese E, Raimondi S, Montagnana M,  Kringen MK et al. Clin Pharmacol Ther. 2019 Jun;105(6):1477-1491.
  
• Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Lancet Psychiatry. 2019 May;6(5):418-426.
  
• Substantial Differences in Serum Concentrations of Psychoactive Drugs Measured in Samples Stored for 2 Days or More on Standard Serum Tubes Versus Serum Tubes Containing Gel Separators. Wollmann BM, Lunde HA, Støten LK, Lunder N, Molden E. Ther Drug Monit. 2019 Jun;41(3):396-400.
  
• Critical appraisal of adverse effects reporting in the 'Treatment for Adolescents WithDepression Study (TADS)'. Westergren T, Narum S, Klemp M. BMJ Open. 2019; 9(3): e026089.
  
• Detection Time of Oxazepam and Zopiclone in Urine and Oral Fluid after Experimental OralDosing. Bruun LD, Kjeldstadli K, Temte V, Birdal M, Bachs L, Langødegård M, Strand DH, Gaare KI, Øiestad E, Høiseth G. J Anal Toxicol. 2019 Jan 7. doi: 10.1093/jat/bky083. [Epub ahead of print].
  
• Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. Haslemo T, Eliasson E, Jukić MM, Ingelman-Sundberg M, Molden E. Br J Clin Pharmacol. 2019; 85(1): 194-201.
  
• An Experimental Study of Diazepam and Alprazolam Kinetics in Urine and Oral Fluid Following Single Oral Doses. Temte V, Kjeldstadli K, Bruun LD, Birdal M, Bachs L, Karinen R, Middelkoop G, Øiestad E, Høiseth G. J Anal Toxicol. 2019 Mar 1;43(2):104-111.
  
• En jente i tidligskolealder uten effekt av opioider ved generell anestesi. Olsen TCR, Rasmussen AR, Kringen MK, Molden E. Tidsskr Nor Laegeforen. 2019;139(7). doi: 10.4045/tidsskr.18.0561.
• Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers. Gjestad C, Hole K, Haslemo T, Diczfalusy U, Molden E. AAPS J. 2019; 21(4): 58.
• Tvangsbehandling av somatisk sykdom ved psykisk lidelse. Bjorå IKH, Jorem J, Tveito M. Tidsskr Nor Laegeforen. 2019 Feb 8;139(3).
  
• HairEtG: Alterations in segment levels accompanying hair growth. Fosen JT, Høiseth G, Sempio C, Giarratana N, Enger A, Mørland J, Morini L. Drug Test Anal. 2019 Jan;11(1):112-118.
• Adipokine levels are associated with insulin resistance in antipsychotics usersindependently of BMI. Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, Rødevand L, Melle I, Andreassen OA, Molden E, Jönsson EG. Psychoneuroendocrinology. 2019; 103: 87-95.
  
• Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants(DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. Viktil KK, Lehre I, Ranhoff AH, Molden E. Drugs Aging 2019; 36(1): 65-71.
  
• Detection of Drugs in Simultaneously Collected Samples of Oral Fluid and Blood. Bakke E, Høiseth G, Arnestad M, Gjerde H. J Anal Toxicol. 2019; 43(3): 228-232.
  

2018

• Farmakologiske aspekter relater til bruk av antidepressiva hos eldre. Waade RB. NFT 2018; 6: 28-30.
• Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-ActingInjectable Formulations: An Observational Study Including 8,288 Patients. Tveito M, Smith RL, Molden E, Haslemo T, Refsum H, Hartberg C, Correll CU, Høiseth G. J Clin Psychopharmacol. 2018; 38(6):570-576.
  
• Free thyroxine and thyroid-stimulating hormone in severe mental disorders: Anaturalistic study with focus on antipsychotic medication. Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, Rødevand L, Melle I, Andreassen OA, Molden E, Jönsson EG. J Psychiatr Res. 2018; 106:74-81.
  
• Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients. Hole K, Heiberg PL, Gjestad C, Mehus LL, Rø Ø, Molden E. Pharmacol Res Perspect. 2018 Sep 11;6(5):e00430.
  
• Lifecourse socioeconomic position, alcohol drinking patterns in midlife, and cardiovascularmortality: Analysis of Norwegian population-based health surveys. Degerud E, Ariansen I, Ystrom E, Graff-Iversen S, Høiseth G, Mørland J, Davey Smith G, Næss Ø. PLoS Med. 2018 Jan 2; 15(1):e1002476.
  
• Fatal Adverse Event with Dabigatran in Elderly Patient with Reduced Kidney Function. Havig SM, Lea D, Krpo M, Skari RM, Gustavsen I, Høiseth G. Basic Clin Pharmacol Toxicol. 2018 Aug; 123(2):221-226.
• Afatal blood concentration of 5-APB. Krpo M, Luytkis HC, Haneborg AM, Høiseth G. Forensic Sci Int. 2018 Oct;291:e1-e3.
  
• Impactof CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: ARetrospective Study Based on 2,087 Patients. Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Am J Psychiatry. 2018; 175(5): 463-70.
  
• Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker. Hole K, Wollmann BM, Nguyen C, Haslemo T, Molden E. Ther Drug Monit. 2018; 40(4): 463-68.
  
• Clinically Relevant Effect of UGT1A4*3 on Lamotrigine Serum Concentration is Restricted toPostmenopausal Females - a Study Matching Therapeutic Drug Monitoring andGenotype Data from 534Patients. Smith RL, Haslemo T, Chan HF, Refsum H, Molden E. Ther Drug Monit. 2018; 40(5): 567-571.
  
• Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition. Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Clin Pharmacol Ther. 2018; 103(3): 477-84.
  
• Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus youngerpatients with epilepsy: A pharmacoepidemiological study of CNS-active drugs inNorway, 2004-2015. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, Molden E, Granas AG, Johannessen SI, Landmark CJ. Epilepsy Res. 2018; 139: 35-42.
  
• Common schizophrenia alleles are enriched in mutation-intolerant genes and in regionsunder strong background selection. Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Et al. inkl Molden E. Nat Genet. 2018; 50(3): 381-89.
  
• Serumkonsentrasjonsmålinger av DOAK-legemidler. Dyrkorn R, Lundgaard H, Stokes CL, Molden E, Spigset O. Tidsskr Nor Laegeforen. 2018; 138(7): doi: 10.4045 /tidsskr.18.0237.
  
• Hvem bør få klopidogrel etter hjerneslag? Ihle-Hansen H, Hagberg G, Molden E, Myrstad M. Tidsskr Nor Laegeforen. 2018; 138(9): doi: 10.4045 /tidsskr.18.0277.
  
• Characterization of gastrointestinal adverse effects reported in clinical studies ofcorticosteroid therapy. Westergren T, Narum S, Klemp M. J Clin Epidemiol. 2018; 94: 19-26.
  
• Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-termpsychiatric inpatient departments. Ringen PA, Faerden A, Antonsen B, Falk RS, Mamen A, Rognli EB, Solberg DK, Andreassen OA, Martinsen EW. Nord J Psychiatry. 2018; 72(4): 296-302.
  
• Using motivational techniques to reduce cardiometabolic risk factors in long termpsychiatric inpatients: a naturalistic interventional study. Ringen PA, Falk RS, Antonsen B, Faerden A, Mamen A, Rognli EB, Solberg DK, Martinsen EW, Andreassen OA. BMC Psychiatry. 2018; 18(1): 255.
  
• The Appearance, Taste, and Concentrations of Zolpidem Dissolved in Still Water andCarbonatedBeverages. Heide G, Hjelmeland K, Brochmann GW, Karinen R, Høiseth G. J Forensic Sci. 2018; 63(3): 911-914.
• Is Hair Analysis Useful in Postmortem Cases? Høiseth G, Arnestad M, Karinen R, Morini L, Rogde S, Sempio C, Vindenes V, Øiestad ÅML.  J Anal Toxicol. 2018; 42(1): 49-54.
  
• Lifecourse socioeconomic position, alcohol drinking patterns in midlife, andcardiovascular mortality: Analysis of Norwegian population-based healthsurveys. Degerud E, Ariansen I, Ystrom E, Graff-Iversen S, Høiseth G, Mørland J, Davey Smith G, Næss Ø. PLoS Med. 2018; 15(1): e1002476.
  
• Fatal Adverse Event with Dabigatran in Elderly Patient with Reduced Kidney Function. Havig SM, Lea D, Krpo M, Skari RM, Gustavsen I, Høiseth G. Basic Clin Pharmacol Toxicol. 2018; 123(2): 221-226.
  
• Associations between cytokine levels and CYP3A4 phenotype in patients with rheumatoid arthritis. Wollmann BM, Syversen SW, Vistnes M, Lie E, Mehus LL, Molden E. Drug Metab Dispos. 2018 oct; 46(10): 1384-9.
  

2017

• Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate – A  national approach to the evaluation of therapeuticdrug monitoring data and clinical outcome. Svendsen T, Brodkorp E, Reimers A, Molden E, Sætre E, Johannesen SI, Johannesen Landmark C. Epilepsy Res. 2017; 129: 125-31.
  
• 4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. Wollmann BM, Syversen SW, Lie E, Gjestad C, Mehus LL, Olsen IC, Molden E. Clin Transl Sci. 2017; 10(1): 42-9.
  
• Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterolconcentration. Hole K, Gjestad C, Heitmann KM, Haslemo T, Molden E, Bremer S. Eur J Clin Pharmacol. 2017; 73(3): 317-24.
  
• Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimusclearance. Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Br J Clin Pharmacol 2017; 83(6): 1350-2.
  
• The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictionsearly after kidney transplantation. Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A. Br J Clin Pharmacol. 2017; 83(7): 1457-65.
  
• 4β-Hydroxycholesterol level significantly correlates with steady-stateserum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. Gjestad C, Haslemo T, Andreassen OA, Molden E. Br J Clin Pharmacol.2017; 83(11): 2398-2405.
  
• Cooperation between geriatricians and general practitioners for improved pharmacotherapy inhome-dwelling elderly people receiving polypharmacy - the COOP Study: studyprotocol for a cluster randomised controlled trial. Romskaug R, Molden E, Straand J, Kersten H, Skovlund E, Pitkala KH, Wyller TB. Trials 2017; 18(1): 158.
  
• Psychotropics and weak opioid analgesics in plasma samples of older hip fracture patients –detection frequencies and consistency with drug records. Waade RB, Molden E, Martinsen MI, Hermann M, Ranhoff AH. Br J Clin Pharmacol. 2017; 83(7): 1397-1404.
  
• Dietary polyunsaturated fatty acids, brain function and mental health. Bentsen H. Microbial Ecology in Health and Disease 2017; 28 (suppl. 1): 1281916.
  
• Cecal microbiota association with tumor load in acolorectal cancer mouse model. Bråten LS, Sødring M, Paulsen JE, Snipen LG, Rudi K. Ecology in Health and Disease 2017; 28(1): 1352433.
  
• EthylGlucuronide Elimination Kinetics in Fingernails and Comparison to Levels inHair. Fosen JT, Morini L, Sempio C, Giarratana N, Enger A, Mørland J, Høiseth G. Alcohol Alcohol. 2017; 52(5): 580-6.
  
• Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drugdisposition. Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. PLoS One. 2017; 12(7): e0181082.
  
• Impairment due to alcohol, tetrahydrocannabinol, and benzodiazepines in impaired driverscompared to experimental studies. Høiseth G, Berg-Hansen GO, Øiestad ÅM, Bachs L, Mørland J. Traffic Inj Prev. 2017; 18(3): 244-50.
  
• Combined effect of CYP2B6 genotype and other candidate genes on a steady-stateserum concentration of methadone in opioid maintenance treatment. Kringen MK, Chalabianloo F, Bernard JP, Bramness JG, Molden E, Høiseth G. Ther Drug Monit 2017; 18(3): 231-6.
  
• Urinary Kinetics of Heroin Metabolites in Pigs Shortly After Intake. Høiseth G, Gottås A, Berg T, Arnestad M, Halvorsen PS, Bachs LC. J Anal Toxicol 2017; 41(5): 451-4.
  
• Prevalence and concentrations of drugs in older suspected drugged drivers. Høiseth G, Austdal LE, Wiik E, Bogstrand ST, Mørland J. Traffic Inj Prev. 2017; 18(3): 231-6.
  
• Recovery of CYP3A Phenotype after Kidney Transplantation. Hole K, Størset E, Olastuen A, Haslemo T, Kro GB, Midtvedt K, Åsberg A, Molden E. Drug Metab Dispos 2017; 45(12): 1260-1265.
  
• Distinct DNA methylation profiles in bone and blood of osteoporotic and healthypostmenopausal women. Reppe S, Lien TG, Hsu YH, Gautvik VT, Olstad OK, Yu R, Bakke HG, Lyle R, Kringen MK, Glad IK, Gautvik KM. Epigenetics. 2017: 12(8): 674-687.
  
• Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels inPatients with Schizophrenia: A Retrospective Observational Study. Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E. CNS Drugs. 2017; 31(11): 991-7.
  
• Individual variability in clinical effect and tolerability of opioid analgesic –Importance of drug interaction and pharmacogenetics. Solhaug V, Molden E. Scand J Pain 2017; 17:193-200.
  
• Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus youngerpatients with epilepsy: A pharmacoepidemiological study of CNS-active drugs inNorway, 2004-2015. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, Molden E, Granas AG, Johannessen SI, Landmark CJ. Epilepsy Res. 2017; 139: 35-42.
  
• Changesin drug disposition of lithium during pregnancy: a retrospective observationalstudy of patient data from two routine therapeutic drug monitoring services inNorway. Westin AA, Brekke M, Molden E, Skogvoll E, Aadal M, Spigset O. BMJ Open. 2017 Mar 1;7(3):e015738.

2016

• Tryggere behandling med serumkonsentrasjonsmåling av de nye antikoagulasjonsmidlene? Lundgaard H, Dyrkorn R, Stokes CL, Molden E, Spigset O. Tidsskr Nor Laegeforen. 2016; 136(18): 1556-60.
• Lipid profiles in schizophrenia associated with clinical traits: a five year follow up study. Solberg DK, Bentsen H, Refsum H, Andreassen OA. BMJ Psychiatry 2016; 16: 299
• Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serumconcentrations of valproic acid -a large-scale study based on naturalistictherapeutic drug monitoring data. Smith RL, Haslemo T, Refsum H, Molden E. Eur J Clin Pharmacol. 2016; 72(9): 1099-104.
  
• Levels of Hair Ethyl Glucuronide in Patients with Decreased Kidney Function:Possibility of Misclassification of Social Drinkers. Fosen JT, Morini L, Sempio C, Ganss R, Mørland J, Høiseth G. Alcohol Clin Exp Res. 2016; 40(3): 451-6.
  
• Ethanol elimination rates at low concentrations based on two consecutive blood samples. Høiseth G, Wiik E, Kristoffersen L, Mørland J. Forensic Sci Int. 2016; 266: 191-196.
  
• Mortality among head trauma patients taking preinjury antithrombotic agents: aretrospective cohort analysis from a Level 1 trauma centre. Narum S, Brørs O, Stokland O, Kringen MK. BMC Emerg Med. 2016; 16(1): 29.
  
• Impactof Ageing on Serum Concentrations of Risperidone and its Active Metabolite inPatients with known CYP2D6 Genotype. Molden E, Waade RB, Hoff M, Haslemo T. Basic Clin Pharmacol Toxicol. 2016; 119(5): 470-5.
  
• Serumkonsentrasjonsmålinger av vanedannende legemidler. Helland A, Berg JA, Gustavsen I, Nordal K, Hilberg T, Aronsen L, Arnestad M, Narum S. Tidsskr Nor Legeforen. 2016; 136(5): 400-2.
  
• Rhabdomyolysis and capillary leak syndrome in a patient treated with topical imiquimod. Norum HM, Kolberg ES, Solhaug V, Nordal K, Aukrust P. Int J Dermatol. 2016; 55(9): 1030-2.
  
• Genetisk betingetvariasjon i bioaktivering av tamoksifen og klopidogrel. Solhaug V, Molden E. Tidsskr Nor Legeforen. 2016; 136(5): 434-6.
  
• Relationship between cytochrome P450polymorphisms and prescribed medication in elderly haemodialysis patients.  Parker K, Aasebø W, Haslemo T, Stavem K. Springerplus. 2016; 5: 350.
  
• Correlates of major medication side effectsinterfering with daily performance: results from a cross-sectional cohort studyof older psychiatric patients. Tveito M, Correll CU, Bramness JG, Engedal K, Lorentzen B, Refsum H, Høiseth G. Int Psychogeriatr. 2016; 28(2): 331-40.
  
• 4β-Hydroxycholesterol correlates with dose butnot steady-state concentration of carbamazepine: indication of intestinal CYP3Ain biomarker formation? Gjestad C, Huynh DK, Haslemo T, Molden E. Br J Clin Pharmacol. 2016; 81(2): 269-76.
  
• Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor MetabolizingGenotype. Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E. Ther Drug Monit. 2016; 38(1):127-34.
  
• Effectof teaching and checklist implementation on accuracy of medication historyrecording at hospital admission. Lea M, Barstad I, Mathiesen L, Mowe M, Molden E. Int J Clin Pharm. 2016; 38(1): 20-4.

2015

• Characteristics of methadone-related fatalities in Norway. Bernard JP, Khiabani HZ, Hilberg T, Karinen R, Slørdal L, Waal H, Mørland J. J Forensic Leg Med. 2015; 36: 114-20.
  
• Evaluation of the hip-flask defence bydetermination of ethyl glucuronide and ethyl sulphate concentrations in blood.  Høiseth G, Berg-Hansen GO, Mørland J. Forensic Sci Int. 2015; 257: 398-402.
  
• Has Previous Abuse of Flunitrazepam Been Replaced by Clonazepam? Høiseth G, Middelkoop G, Mørland J, Gjerde H. Eur Addict Res. 2015; 21(4): 217-21.
  
• Ti bud for behandling med psykofarmaka. Solberg DK, Refsum H. Tidsskr Nor Legeforen. 2015; 135(1): 16-7.
  
• Association between serum lipids and membranefatty acids and clinical characteristics in patients with schizophrenia.  Solberg DK, Bentsen H, Refsum H, Andreassen OA. Acta Psychiatr Scand. 2015; 132(4): 293-300.
• Impactof genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations ofquetiapine and N-desalkylquetiapine in psychiatric patients. Bakken GV, Molden E, Hermann M. Ther Drug Monit. 2015; 37(2): 256-61.
  
• Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients. Hermann M, Waade RB, Molden E. Ther Drug Monit. 2015; 37(4): 546-9.
  
• Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion andHydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic DrugMonitoring Data. Høiseth G, Haslemo T, Uthus LH, Molden E. Ther Drug Monit. 2015; 37(5): 589-93.